CORAL GABLES, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- MSP Recovery, Inc. d/b/a LifeWallet (NASDAQ: LIFW) ("LifeWallet," or the "Company"), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery and technology leader, announced it has filed its quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2023.
Recent Highlights
Third Quarter 2023 Financial Highlights
Assigned Recovery Rights Claims Paid and Billed Value
The table below outlines the Company's growth in claims data received in the most recent periods. The amounts represent data received from current and new assignors:
Nine months ended September 30, 2023 | Year Ended December 31, 2022 | Year Ended December 31, 2021 | Year Ended December 31, 2020 | |||||||||
$ in billions | ||||||||||||
Paid Amount | $ | 381.1 | $ | 374.8 | $ | 364.4 | $ | 58.4 | ||||
Paid Value of Potentially Recoverable Claims | 91.5 | 89.6 | 86.6 | 14.7 | ||||||||
Billed Value of Potentially Recoverable Claims | 387.1 | 377.8 | 363.2 | 52.3 | ||||||||
Recovery Multiple | N/A(1) | N/A(1) | N/A(1) | N/A(1) | ||||||||
Penetration Status of Portfolio | 86.6 | % | 85.8 | % | 75.6 | % | N/A |
Financial Outlook
Recoveries Guidance: Recoveries are dependent on the completion of litigation and the negotiation of settlements, which are inherently uncertain and are subject to risk of delay and litigation outcomes. As a result, the Company will not provide future guidance on recoveries that are dependent on litigation or subrogation.
Additional information regarding the non-GAAP financial measures discussed in this release, including an explanation of these measures and how each is calculated, is included below under the heading “Non-GAAP Financial Measures.” A reconciliation of GAAP to non-GAAP financial measures has also been provided in the financial tables included below.
MSP RECOVERY, INC. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited) | |||||||
September 30, | December 31, | ||||||
(In thousands except per share amounts) | 2023 | 2022 | |||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 6,659 | $ | 3,661 | |||
Restricted cash | — | 11,420 | |||||
Accounts receivable | 706 | 6,195 | |||||
Affiliate receivable (1) | 831 | 2,425 | |||||
Prepaid expenses and other current assets (1) | 14,874 | 27,656 | |||||
Total current assets | 23,070 | 51,357 | |||||
Property, plant and equipment, net | 4,890 | 3,432 | |||||
Intangible assets, net (2) | 3,253,707 | 3,363,156 | |||||
Right-of-use assets | 368 | — | |||||
Total assets | $ | 3,282,035 | $ | 3,417,945 | |||
LIABILITIES AND EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 6,643 | $ | 8,422 | |||
Affiliate payable (1) | 19,822 | 19,822 | |||||
Commission payable | 829 | 545 | |||||
Derivative liability | — | 9,613 | |||||
Warrant liability | 662 | 5,311 | |||||
Other current liabilities | 14,588 | 72,002 | |||||
Total current liabilities | 42,544 | 115,715 | |||||
Guaranty obligation (1) | 900,455 | 787,945 | |||||
Claims financing obligation and notes payable (1) | 513,450 | 198,489 | |||||
Lease liabilities | 264 | — | |||||
Loan from related parties (1) | 130,709 | 125,759 | |||||
Interest payable (1) | 50,951 | 2,765 | |||||
Total liabilities | $ | 1,638,373 | $ | 1,230,673 | |||
Commitments and contingencies (Note 12) | |||||||
Class A common stock subject to possible redemption, 45,183 shares at redemption value as of December 31, 2022 (None as of September 30, 2023) | $ | — | $ | 1,807 | |||
Stockholders’ Equity (Deficit): | |||||||
Class A common stock, $0.0001 par value; 5,500,000,000 shares authorized; 13,799,230 and 2,984,212 issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | $ | 1 | $ | - | |||
Class V common stock, $0.0001 par value; 130,000,000 shares authorized; 124,264,645 and 125,919,180 issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | 12 | 13 | |||||
Additional paid-in capital | 347,376 | 137,069 | |||||
Accumulated deficit | (62,094 | ) | (29,203 | ) | |||
Total Stockholders’ Equity (Deficit) | 285,295 | 107,879 | |||||
Non-controlling interest | 1,358,367 | 2,077,586 | |||||
Total equity | $ | 1,643,662 | $ | 2,185,465 | |||
Total liabilities and equity | $ | 3,282,035 | $ | 3,417,945 |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
MSP RECOVERY, INC. and Subsidiaries Condensed Consolidated Statements of Operations (As Restated) (Unaudited) | |||||||||||||||
Three months ended September 30, | Nine months ended September 30, | ||||||||||||||
(In thousands except per share amounts) | 2023 | 2022 | 2023 | 2022 | |||||||||||
As Restated | As Restated | ||||||||||||||
Claims recovery income | $ | 440 | $ | 2,759 | $ | 6,479 | $ | 4,225 | |||||||
Claims recovery service income (1) | — | 5,748 | 498 | 17,795 | |||||||||||
Total Claims Recovery | $ | 440 | $ | 8,507 | $ | 6,977 | $ | 22,020 | |||||||
Operating expenses | |||||||||||||||
Cost of claim recoveries (2) | 574 | 1,198 | 1,972 | 1,906 | |||||||||||
Claims amortization expense | 121,008 | 111,851 | 355,481 | 153,560 | |||||||||||
General and administrative (3) | 6,130 | 6,621 | 20,691 | 17,049 | |||||||||||
Professional fees | 2,466 | 5,904 | 15,611 | 10,973 | |||||||||||
Professional fees – legal (4) | 6,871 | 8,014 | 25,889 | 34,251 | |||||||||||
Allowance for credit losses | — | — | 5,000 | — | |||||||||||
Depreciation and amortization | 85 | 103 | 182 | 254 | |||||||||||
Total operating expenses | 137,134 | 133,691 | 424,826 | 217,993 | |||||||||||
Operating Loss | $ | (136,694 | ) | $ | (125,184 | ) | $ | (417,849 | ) | $ | (195,973 | ) | |||
Interest expense (5) | (88,279 | ) | (46,180 | ) | (204,287 | ) | (80,947 | ) | |||||||
Other income, net | 408 | 63,138 | 8,697 | 63,175 | |||||||||||
Change in fair value of warrant and derivative liabilities | 348 | 2,670 | 4,247 | (11,683 | ) | ||||||||||
Net loss before provision for income taxes | $ | (224,217 | ) | $ | (105,556 | ) | $ | (609,192 | ) | $ | (225,428 | ) | |||
Provision for income tax expense | - | — | — | — | |||||||||||
Net loss | $ | (224,217 | ) | $ | (105,556 | ) | $ | (609,192 | ) | $ | (225,428 | ) | |||
Less: Net loss attributable to non-controlling members | 204,462 | 103,484 | 576,301 | 221,476 | |||||||||||
Net loss attributable to controlling members | $ | (19,755 | ) | $ | (2,072 | ) | $ | (32,891 | ) | $ | (3,952 | ) | |||
Basic and diluted weighted average shares outstanding, Class A Common Stock | 12,703,472 | 2,761,476 | 7,097,032 | 2,125,539 | |||||||||||
Basic and diluted net loss per share, Class A Common Stock | $ | (1.56 | ) | $ | (0.75 | ) | $ | (4.63 | ) | $ | (1.86 | ) |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Non-GAAP Financial Measures
MSP RECOVERY, INC. and Subsidiaries Non-GAAP Reconciliation | |||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
(In thousands) | 2023 | 2022 | 2023 | 2022 | |||||||||||
GAAP Operating Loss | $ | (136,694 | ) | $ | (125,184 | ) | $ | (417,849 | ) | $ | (195,973 | ) | |||
Share-based compensation | 1,875 | — | 1,875 | 20,055 | |||||||||||
Claims amortization expense | 121,008 | 111,851 | 355,481 | 153,560 | |||||||||||
Allowance for credit losses | — | — | 5,000 | — | |||||||||||
Adjusted operating loss | $ | (13,811 | ) | $ | (13,333 | ) | $ | (55,493 | ) | $ | (22,358 | ) | |||
GAAP Net Loss | $ | (224,217 | ) | $ | (105,556 | ) | $ | (609,192 | ) | $ | (225,428 | ) | |||
Share-based compensation | 1,875 | — | 1,875 | 20,055 | |||||||||||
Gain on debt extinguishment | — | (63,367 | ) | — | (63,367 | ) | |||||||||
Claims amortization expense | 121,008 | 111,851 | 355,481 | 153,560 | |||||||||||
Allowance for credit losses | — | — | 5,000 | — | |||||||||||
Paid-in-kind Interest | 88,279 | 46,180 | 204,287 | 80,947 | |||||||||||
Change in fair value of warrant and derivative liabilities | (348 | ) | (2,670 | ) | (4,247 | ) | 11,683 | ||||||||
Adjusted net loss | $ | (13,403 | ) | $ | (13,562 | ) | $ | (46,796 | ) | $ | (22,550 | ) |
The Company considers “adjusted net loss” and “adjusted operating loss” as non-GAAP financial measures and important indicators of performance and useful metrics for management and investors to evaluate the Company’s ongoing operating performance on a consistent basis across reporting periods. The Company believes these measures provide useful information to investors. Adjusted net loss represents Net loss adjusted for certain non-cash expenses and adjusted operating loss items represents Operating loss adjusted for certain non-cash expenses.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intend," "plan" and "will" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts, including for example guidance for 2022 portfolio recovery and total gross recoverables. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, these statements are not guarantees of future performance or results and actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by MSP Recovery herein speaks only as of the date made. New risks and uncertainties come up from time to time, and it is impossible for the Company to predict or identify all such events or how they may affect it. the Company has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. Factors that could cause these differences include, but are not limited to, the Company’s ability to capitalize on its assignment agreements and recover monies that were paid by the assignors; the inherent uncertainty surrounding settlement negotiations and/or litigation, including with respect to both the amount and timing of any such results; the success of the Company's scheduled settlement mediations; the validity of the assignments of claims to the Company; the ability to successfully expand the scope of the Company’s claims or obtain new data and claims from the Company’s existing assignor base or otherwise; the Company’s ability to innovate and develop new solutions, and whether those solutions will be adopted by the Company’s existing and potential assignors; negative publicity concerning healthcare data analytics and payment accuracy; and those other factors included in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed by it with the SEC. These statements constitute the Company's cautionary statements under the Private Securities Litigation Reform Act of 1995.
About LifeWallet
Founded in 2014 as MSP Recovery, LifeWallet has become a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery leader, disrupting the antiquated healthcare reimbursement system with data-driven solutions to secure recoveries from responsible parties. LifeWallet provides comprehensive solutions for multiple industries including healthcare, legal, education, and sports NIL, while innovating technologies to help save lives. For more information, visit: lifewallet.com
Last Trade: | US$1.72 |
Daily Change: | -0.09 -4.97 |
Daily Volume: | 16,143 |
Market Cap: | US$127.000M |
November 14, 2024 September 01, 2023 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load